Article

A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within EU Between 2011 and 2020

2026-01-21

Abstract excerpt

<h4>Background: </h4> Pharmaceutical innovation plays a vital role in advancing global health. This study evaluates the landscape of pharmaceutical innovation in the European Union (EU) over the 2011-2020 decade. <h4>Methods:</h4> A retrospective analysis was performed on new medicinal products containing new active substances (NAS) authorized between 2011 and 2020 through the centralized procedure. Products were...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1165eb4c-7c58-50eb-8da6-321ce7f6c45a
DOI: 10.20944/preprints202601.1582.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Decade of Innovation: Medicinal Products with New Active Substances Centrally Authorized Within EU Between 2011 and 2020DOI 10.20944/preprints202601.1582.v1Read

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read

Launch Sequencing of Pharmaceuticals with Multiple Therapeutic Indications: Evidence from Seven CountriesSemantic proximity Read

Academic challenges on ATMPs’ development: a regulatory perspectiveSemantic proximity Read

Development Analysis and Strategic Insights from a 505(b)(2) Reformulation Product: EnzalutamideSemantic proximity Read

Analysis of Patient Access to Orphan Drugs in TurkeySemantic proximity Read

Time to Patients’ Access to New Medicines in Greece: Evaluation of Health Technology Assessment (HTA) Process from July 2018 until January 2021.Semantic proximity Read

Drug discovery and development in the age of molecular medicine.Semantic proximity Read

Calendar Period Estimation of Probabilities of Transition in Drug DevelopmentSemantic proximity Read

“The drug development pipeline for glioblastoma - a cross sectional assessment of the FDA Orphan Drug Product designation database”Semantic proximity Read

Pharmaceutical Drug Lifecycle: A Comprehensive Scientific Review of Research and Development Phases, Attrition Rates, and Global DisparitiesSemantic proximity Read

Lifecycle management of orphan drugs approved in JapanSemantic proximity Read

Trend Analysis of Regulatory Approval Pathways and Major Shifts in Pivotal Clinical Trial Designs for Antineoplastic Drugs Approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) From 2004 to 2019.Semantic proximity Read